Care home residents gain 62% protection from single dose of COVID-19 vaccine

Care home residents gain 62% protection from single dose of COVID-19 vaccine
Credit: Mat Napo on Unsplash

A single dose of either the Oxford-AstraZeneca or Pfizer vaccines gives residents of care homes substantial protection against SARS-CoV-2 infection after four weeks, according to new pre-print findings from the Vivaldi study led by UCL researchers.

The study, funded by the Department of Health and Social Care, looked at data from more than 10,000 care home residents in England, with an average age of 86, between December and mid-March, comparing the number of infections occurring in vaccinated and unvaccinated groups (as identified by the gold-standard PCR test.)

It found that a single dose was effective at preventing 56% of infections after four weeks, rising to 62% of infections after five weeks. Looking at the Pfizer and Oxford-AstraZeneca vaccines separately, they found that the timing and size of the protective effect was similar for both vaccines.

Dr. Maddie Shrotri (UCL Institute of Health Informatics) said: "Our study suggests that both vaccines currently in use in the UK are effective at reducing infections in frail, older adults. This new evidence is important because there is currently limited data about vaccine efficacy for this vulnerable population."

Researchers also found evidence suggesting the infections occurring post-vaccine may be less infectious. Analysing lab samples from positive PCR tests, they found that samples taken at least 28 days after the first vaccine dose contained less of the virus, meaning they were "weaker" positives.

Dr. Laura Shallcross (UCL Institute of Health Informatics) said: "Our findings show that a single dose has a protective effect that persists from four weeks to at least seven weeks after vaccination. Vaccination reduces the total number of people who get infected, and analysis of lab samples suggests that care home residents who are infected after having the vaccine may also be less likely to transmit the virus.

"We can also infer that the vaccines protect against the highly transmissible UK variant, as this was prevalent during the study period."

Chief Medical Officer for England, Professor Chris Whitty said: "These data add to the growing evidence that vaccines are reducing COVID-19 infections and doing so in vulnerable and older populations, where it is most important that we provide as much protection from COVID as possible."

Minister for Care, Helen Whately said: "This virus sadly has the most serious and profound effect on older people living in care homes and making sure they are protected has been our priority for the last year.

"It is brilliant to see this is having the positive effect the science suggested, not only by preventing death, but also reducing the chance of infection.

"This is particularly important in keeping those most at risk from the virus safe."

The study looked at PCR test result data for 10,412 long-term care home residents from 310 care homes. The residents were all over the age of 65, and had routine monthly PCR tests as well as further targeted tests if an outbreak was suspected. The data included a total of 36,352 PCR results, of which 1,335 were positive.

Researchers estimated the effectiveness of the vaccine by looking at the number of infections within specific time periods after vaccination (e.g., 0-6 days, 7-13 days, 14-28 days, up to seven weeks) and comparing these to the number of infections that occurred before vaccination. From this, they calculated that the risk of infection was 56% lower four weeks after vaccination, and 62% lower after five weeks.

Among who had previously been infected by SARS-CoV-2, a single vaccine dose appeared to have little impact, suggesting people who have a prior are already well protected. However, only 11% of people in the study had been infected with SARS-CoV-2 before, so these early findings require further research.

The researchers also looked at the Ct values of the PCR-positive tests. The Ct value is the number of cycles it takes to detect the viral DNA—a higher Ct value means there is less viral material to detect and suggests a lower level of infectiousness (transmissibility). The researchers found a higher average Ct value for positive tests 28 days after vaccination compared to positive tests before vaccination (an average Ct value of 31.3 compared to 26.6).

The research is part of the ongoing Vivaldi study, launched in June last year, to investigate COVID-19 infections in care homes and inform strategies to protect residents. The study is a collaboration between researchers from UCL and the University of Birmingham and healthcare providers including Four Seasons Healthcare, HC-One, The Orders of St John Care Trust, and Friends Of The Elderly.

Dr. Shallcross added: "This timely evidence on the real-world effectiveness of vaccines shows the value of collaboration between care homes and research teams. We would like to thank the who shared their data with us."

Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

More information: Madhumita Shrotri et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study), medrxiv (2021). DOI: 10.1101/2021.03.26.21254391
Citation: Care home residents gain 62% protection from single dose of COVID-19 vaccine (2021, March 30) retrieved 8 May 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments